Unravelling the Genetic Tapestry of Immunity: A Comprehensive Review of Immunogenetics
DOI:
https://doi.org/10.64229/71q2ja58Keywords:
Immunogenetics, HLA polymorphism, Immune tolerance, Next-generation sequencing (NGS), CRISPR-Cas9, Multi-omics, Precision medicineAbstract
The overlap of immunology and genetics has become immunogenetics, an exciting new field that promises to reveal previously inaccessible details of interactions between genetic variation and immune reactions, disease development and resolution, drug efficacy and tolerance. As global health is increasingly influenced by immune-mediated disorders and it spans autoimmune disease, cancer, and new emerging infectious risks, precision, population-specific interventions have never been more urgent. This review brings together fundamental immunogenetics and translational research under one umbrella, discussing the contributions of HLA polymorphism, the diversity of antibody/T-cell receptor, cytokine networks, and immune checkpoint regulation in the development of antigen recognition and immune tolerance. We explain disruptive technologies, such as next-generation sequencing, CRISPR-Cas9, and integrative multi-omics, that are redefining the field of diagnostics and therapeutics. Certain persistent issues cannot be ignored, e.g., equal utilization of genetic information amongst human genetic variations, ethical management of genetic information, and biomarker validation are equally evaluated. We propose the future directions using systems biology, consortia of global genomics, and predictive modelling made possible through AI as the basis of next-generation precision medicine, with the next factor of precision medicine being immunogenetics.
References
[1]Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, et al., Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Diseases, 2018, 18(3), e64-e75. DOI: 10.1016/S1473-3099(17)30623-0
[2]Nguyen KHH, Le NV, Nguyen PH, Nguyen HHT, Hoang DM, Huynh CD. Human immune system: Exploring diversity across individuals and populations. Heliyon, 2025, 11(2), e41836. DOI: 10.1016/j.heliyon.2025.e41836
[3]Walter JE, Ziegler JB, Ballow M, Cunningham-Rundles C. Advances and challenges of the decade: the ever-changing clinical and genetic landscape of immunodeficiency. The Journal of Allergy and Clinical Immunology: In Practice, 2023, 11(1), 107-115. DOI: 10.1016/j.jaip.2022.11.007
[4]Menon AV, Song B, Chao L, Sriram D, Chansky P, Bakshi I, et al. Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology. Frontiers in Genome Editing, 2025, 7, 1565387. DOI: 10.3389/fgeed.2025.1565387
[5]Eslami M, Dowlat BF, Yaghmayee S, Habibian A, Keshavarzi S, Oksenych V, et al. Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity. Vaccines, 2025, 13(6), 588. DOI: 10.3390/vaccines13060588
[6]Chen YM, Hsiao TH, Lin CH, Fann YC. Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence. Journal of Biomedical Science, 2025, 32(1), 16. DOI: 10.1186/s12929-024-01110-w
[7]Kaszycki J, Kim M. Epigenetic regulation of transcription factors involved in NLRP3 inflammasome and NF-kB signaling pathways. Frontiers in Immunology, 2025, 16, 1529756. DOI: 10.3389/fimmu.2025.1529756
[8]Nalbant E, Akkaya-Ulum YZ. Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases. Clinical and Experimental Medicine, 2024, 24(1), 142. DOI: 10.1007/s10238-024-01334-y
[9]Zhang Y. Factor-based approaches for molecular signature discovery in psychotic disorders. Doctoral dissertation, Institute of Pharmacy and Molecular Biotechnology, Heidelberg, 2024. DOI: 10.11588/heidok.00035513
[10]Vicente MM, Leite-Gomes E, Pinho SS. Glycome dynamics in T and B cell development: basic immunological mechanisms and clinical applications. Trends in Immunology, 2023, 44(8), 585-597. DOI: 10.1016/j.it.2023.06.004
[11]Noor S, Fatima A, Fatima I, Javed A. Antigen-Antibody Interaction in Cell Signaling. In Cell Signaling, 2025, CRC Press, 92-125.
[12]Monos DS, Winchester RJ. The major histocompatibility complex. Clinical Immunology, 2019, 79-92. DOI: 10.1016/B978-0-7020-6896-6.00005-3
[13]He C, Han XX, Zhang H, Jiang FM, An MH, Zhao B. High polymorphism rates in well-known T cell epitopes restricted by protective HLA alleles during HIV infection are associated with rapid disease progression in early-infected MSM in China. Medical Microbiology and Immunology, 2019, 208(2), 239-251. DOI: 10.1007/s00430-019-00585-x
[14]Acha-Orbea H, McDevitt HO, Steinman L. T Cell Receptor and Autoimmune Disease. The Immunogenetics of Autoimmune Diseases, CRC Press, Volume I, 2024, 99-123.
[15]Christiansen OB. Recurrent pregnancy loss. John Wiley & Sons, 2013. DOI:10.1002/9781118749012
[16]Cohen I. Natural Machine Learning (NML) Shapes the Adaptive Immune System. Immunology and Microbiology, 2025. DOI: 10.20944/preprints202505.0563.v1
[17]Ünlü B, Türsen Ü, Rajabi Z, Jabalameli N, Rajabi F. The immunogenetics of systemic sclerosis. Immunogenetics of Dermatologic Diseases, 2022, 1367, 259-298. DOI: 10.1007/978-3-030-92616-8_10
[18]Patas K, Baker D, Chrousos G, Agorastos A. Inflammation in posttraumatic stress disorder: Dysregulation or recalibration? Current Neuropharmacology, 2024, 22(4), 524-542. DOI:10.2174/1570159X21666230807152051
[19]van Wesemael TJ, Morton FR, Heutz JW, Maurits MP, Dorjée AL, Porter D, et al. Smoking as a risk factor for rheumatoid arthritis: predominant association with IgA autoantibodies–comprehensive analysis of anti-modified protein antibodies with smoking and genetic risk factors in rheumatoid arthritis. Arthritis Research & Therapy, 2025, 27(1), 101. DOI: 10.1186/s13075-025-03543-6
[20]Guyer P, Seminova K, Lugar M, Manganaro A, Velarde de la Cruz EE, Hartley R, et al. T cell and autoantibody recognition of nucleus-associated islet autoantigens in individuals with type 1 diabetes. Diabetologia, 2025, 68(8), 1721-1734. DOI: 10.1007/s00125-025-06458-8
[21]Arowosegbe A. Mechanisms of Interferon-α/β Receptor (IFNAR) Dependent and Independent Autoimmune Diabetes in LEW. 1WR1 Rats, 2024. DOI: 10.13028/x6y1-3k16
[22]Visha E. Massively parallel reporter assay (MPRA) combined with bayesian fine mapping approaches prioritize variants associated with multiple sclerosis (MS) from genome wide association studies (GWAS) with a potential functional role and interaction with environmental factors, Universita degli Studi del Piemonte Orientale Amedeo Avogadro, Vercelli, 136, 2025.
[23]Funes SC, Fernández-Fierro A, Rebolledo-Zelada D, Mackern-Oberti JP, Kalergis AM. Contribution of dysregulated DNA methylation to autoimmunity. International Journal of Molecular Sciences, 2021. 22(21), 11892. DOI: 10.3390/ijms222111892
[24]Radwell J. The Immunogenome: A Blueprint for Immunity, Disease, and Longevity. Black Mill Publishing, 2025.
[25]Butta G. Heterogeneity of Latency Establishment in the Different Human CD4+ T Cell Subsets Stimulated with IL-15. Journal of Virology, 2023, 96(10), e0037922. DOI: 10.1128/jvi.00379-22
[26]Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity, 2012, 37(3), 426-440. DOI: 10.1016/j.immuni.2012.09.005
[27]Sahay B, Nguyen QC, Yamamoto JK. Conserved HIV epitopes for an effective HIV vaccine. Journal of Clinical & Cellular Immunology, 2017, 8(4), 518. DOI: 10.4172/2155-9899.1000518
[28]Liebrich W, Esser M, Emanuel S. Mendelian susceptibility to mycobacterial disease (MSMD). Current Allergy & Clinical Immunology, 2018, 31(1), 45-46.
[29]Hütter G, Ganepola S. The CCR5-delta32 polymorphism as a model to study host adaptation against infectious diseases and to develop new treatment strategies. Experimental Biology and Medicine, 2011, 236(8), 938-943. DOI: 10.1258/ebm.2011.010241
[30]Lima-Junior JDC, Pratt-Riccio LR. Major histocompatibility complex and malaria: focus on Plasmodium vivax infection. Frontiers in Immunology, 2016, 7, 13. DOI: 10.3389/fimmu.2016.00013
[31]Zepeda-Cervantes J, Martínez-Flores D, Ramírez-Jarquín JO, Tecalco-Cruz AC, Alavez-Pérez NS, Vaca L, et al. Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19. Viruses, 2022, 14(1), 94. DOI: 10.3390/v14010094
[32]David C. TLR mediated inflammatory disease and other type I interferonopathies. Université Paris Cité, 2024.
[33]Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. Journal of Internal Medicine, 2016, 279(6), 541-562. DOI: 10.1111/joim.12470
[34]Zhang H, Dai ZY, Wu WT, Wang ZY, Zhang N, Zhang LY. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research, 2021, 40(1), 184. DOI: 10.1186/s13046-021-01987-7
[35]Wang JC, Sun L. PD-1/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph (-) myeloproliferative neoplasm: a review. International Journal of Molecular Sciences, 2022, 23(10), 5837. DOI: 10.3390/ijms23105837
[36]Parakh S, Musafer A, Paessler S, Witkowski T, Li Wai Suen CSN, Tutuka CSA, et al. PDCD1 polymorphisms may predict response to anti-PD-1 blockade in patients with metastatic melanoma. Frontiers in Immunology, 2021, 12, 672521. DOI: 10.3389/fimmu.2021.672521
[37]Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open, 2022, 7(1), 100336. DOI: 10.1016/j.esmoop.2021.100336
[38]Pagliuca S, Gurnari C, Rubio MT, Visconte V, Lenz TL. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Frontiers in Immunology, 2022, 13, 944872. DOI: 10.3389/fimmu.2022.944872
[39]Saadh MJ, Rasulova I, Khalil M, Farahim F, Sârbu I, Ciongradi CI, et al. Natural killer cell-mediated immune surveillance in cancer: Role of tumor microenvironment. Pathology-Research and Practice, 2024, 254, 155120. DOI: 10.1016/j.prp.2024.155120
[40]Specchia M, Siringo M, Mazzotti E, Mazzuca F. Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic Review, 2025. DOI: 10.20944/preprints202506.0058.v1
[41]Guo AJ, Deng QY, Pan D, Zhou L, Shi L. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors. World Journal of Clinical Oncology, 2024, 15(8), 1002. DOI: 10.5306/wjco.v15.i8.1002
[42]Floudas CS, Sarkizova S, Ceccarelli M, Zheng W. Leveraging mRNA technology for antigen based immuno-oncology therapies. Journal for Immunotherapy of Cancer, 2025, 13(1), e010569. DOI: 10.1136/jitc-2024-010569
[43]La Rocca U, Perrone P, Piciocchi A, Barberi W, Gesuiti P, Laurenti L. Donor specific anti-HLA antibodies in Hematopoietic Stem Cell Transplantation. Single Center prospective evaluation and desensitization strategies employed. Blood Transfusion, 2024, 22(2), 157-165. DOI: 10.2450/BloodTransfus.464
[44]Senev A, Tambur AR, Kosmoliaptsis V, Copley HC, García-Sánchez C, Usenko C, et al. HLA molecular mismatches and induced donor-specific tolerance in combined living donor kidney and hematopoietic stem cell transplantation. Frontiers in Immunology, 2024, 15, 1377535. DOI: 10.3389/fimmu.2024.1377535
[45]Bodade A, Bodade RG. Basics of Human Leukocyte Antigens (HLA) System and ITS Applaication in Clinical Specialties. Int J Med Lab Res, 2020, 5(2), 51-68. DOI: 10.35503/IJMLR.2020.5207
[46]Sutanto H, Maimunah U, Fetarayani D. Donor-specific antibodies and their impact on antibody-mediated rejection post-liver transplantation: a comprehensive review. Journal of Liver Transplantation, 2024, 14, 100214. DOI: 10.1016/j.liver.2024.100214
[47]Legaz I, Bolarín JM, Campillo JA, Moya-Quiles MR, Miras M, Muro M, et al. Killer cell immunoglobulin-like receptors (KIR) and human leucocyte antigen C (HLA-C) increase the risk of long-term chronic liver graft rejection. International Journal of Molecular Sciences, 2022, 23(20), 12155. DOI: 10.3390/ijms232012155
[48]Al Nasser MS. The Impact of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on the Clinical Outcomes of Tacrolimus in Saudi kidney Transplant Patients. King Abdulaziz University Jeddah, 2020.
[49]Chen L, Zhao JN, Meng QL. From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis. Frontiers in Immunology, 2025, 16, 1556971. DOI: 10.3389/fimmu.2025.1556971
[50]Regnell SE, Lernmark A. Early prediction of autoimmune (type 1) diabetes. Diabetologia, 2017, 60(8), 1370-1381. DOI: 10.1007/s00125-017-4308-1
[51]Kaewpreedee P. CTL-mediated immune evasion in hiv viraemic controllers and non-controllers. Chulalongkorn University, 2017. DOI: 10.58837/CHULA.THE.2017.348
[52]Harris KM. Investigation of the IL-23 response to wheat gliadin, the primary etiologic agent in celiac disease. University of Maryland, Baltimore, 2008.
[53]Nasr A. Single nucleotide polymorphisms related to immune responses in Plasmodium falciparum malaria. Wenner-Grens Institut for Experimentell Biologi, 2008.
[54]Zhang X, Wu T, Cai XY, Dong JH, Xia CF, Zhou YC, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Frontiers in Immunology, 2022, 13, 795972. DOI: 10.3389/fimmu.2022.795972
[55]Colomar-Carando N. Novel insights into NK cell/leukemia molecular interactions and possible tools to potentiate the anti-leukemia NK cell activity. University of Genoa, 2022.
[56]Caragea AM, Bohiltea LC, Constantinescu A, Constantinescu I, Ursu RI. NGS and Immunogenetics: Sequencing the HLA Genes. DNA Sequencing-History, Present and Future: History, Present and Future, 2025, 99. DOI: 10.5772/intechopen.1008527
[57]Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, et al. T-cell receptor repertoire sequencing and its applications: focus on infectious diseases and cancer. International Journal of Molecular Sciences, 2022, 23(15), 8590. DOI: 10.3390/ijms23158590
[58]Brown AJ. The Effect of MHC Heterozygosity on T Cell Receptor Diversity. University of Colorado Denver, Anschutz Medical Campus, 2024.
[59]Han H, Sun XY, Guo XY, Wen JX, Zhao XM, Zhou, WQ. CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects. Frontiers in Pharmacology, 2025, 16, 1552741. DOI: 10.3389/fphar.2025.1552741
[60]Shahrajabian MH, Sun W. Survey on multi-omics, and multi-omics data analysis, integration and application. Current Pharmaceutical Analysis, 2023, 19(4), 267-281. DOI: 10.2174/1573412919666230406100948
[61]Hellman D. What makes genetic discrimination exceptional? American Journal of Law & Medicine, 2003, 29(1), 77-116.
[62]Scott M. We are Pretty Sure We Can Never Say Never: Exploring how Risk and Uncertainty Communication Impacts Care in Public Genetic Counseling Consultations in South Africa. University of the Witwatersrand, Faculty of Humanities, School of Human and Community Development, 2021.
[63]Sarsani V, Brotman SM, Xianyong Y, Silva LF, Laakso M, Spracklen CN. A cross-ancestry genome-wide meta-analysis, fine-mapping, and gene prioritization approach to characterize the genetic architecture of adiponectin. Human Genetics and Genomics Advances, 2024, 5(1), 100252. DOI: 10.1016/j.xhgg.2023.100252
[64]Jara L, Gonzalez-Hormazabal P, Cerceño K, Di Capua GA, Reyes JM, Blanco R, et al. Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Breast Cancer Research and Treatment, 2013, 137(2), 559-569. DOI: 10.1007/s10549-012-2359-z
[65]Rotimi C. H3Africa: Human Heredity and Health in Africa. Conference to Eliminate Heath Disparities in Genomic Medicine, the Role of Policy, Washington, DC, September, 2014, 4-5.
[66]Chu XJ, Zhang B, Koeken VACM, Gupta MK, Li Y. Multi-omics approaches in immunological research. Frontiers in Immunology, 2021, 12, 668045. DOI: 10.3389/fimmu.2021.668045
[67]Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature, 2016, 538(7624), 161-164. DOI:10.1038/538161a
[68]Enitan SS, Adejumo EN, Osakue OE, Eke SS, Akele RY, Edafetanure-Ibeh OM, et al.. Integrating genomics and proteomics technologies in biological research: Advantages, challenges, and prospects. Global South Health Horizons, 2025, 1(1), 12-35. DOI: 10.63950/gshh.2025.1.1.2
[69]Li YW, Wu X, Fang DY, Luo Y. Informing immunotherapy with multi-omics driven machine learning. NPJ Digital Medicine, 2024, 7(1), 67. DOI: 10.1038/s41746-024-01043-6
